Anixa Biosciences Files 8-K

Ticker: ANIX · Form: 8-K · Filed: Mar 21, 2025 · CIK: 715446

Anixa Biosciences Inc 8-K Filing Summary
FieldDetail
CompanyAnixa Biosciences Inc (ANIX)
Form Type8-K
Filed DateMar 21, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, financial-reporting

TL;DR

Anixa Biosciences filed an 8-K on 3/20/25 covering votes, Reg FD, and financials.

AI Summary

Anixa Biosciences, Inc. filed an 8-K on March 20, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements. The company, formerly known as ITUS Corp and COPYTELE INC, is incorporated in Delaware and headquartered in San Jose, California.

Why It Matters

This filing provides updates on corporate governance and financial reporting, which are crucial for investors to understand the company's operational status and compliance.

Risk Assessment

Risk Level: low — This is a routine filing reporting on standard corporate events and disclosures, not indicating any immediate material changes or risks.

Key Players & Entities

  • Anixa Biosciences, Inc. (company) — Registrant
  • ITUS Corp (company) — Former company name
  • COPYTELE INC (company) — Former company name
  • Delaware (jurisdiction) — State of incorporation
  • San Jose, CA (location) — Principal executive offices
  • March 20, 2025 (date) — Date of earliest event reported

FAQ

What are the main items reported in this 8-K filing?

This 8-K filing reports on Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on March 20, 2025.

What is the exact name of the registrant?

The exact name of the registrant is Anixa Biosciences, Inc.

In which state is Anixa Biosciences, Inc. incorporated?

Anixa Biosciences, Inc. is incorporated in Delaware.

What is the address of Anixa Biosciences, Inc.'s principal executive offices?

The address of Anixa Biosciences, Inc.'s principal executive offices is 3150 Almaden Expressway, Suite 250, San Jose, CA 95118.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 21, 2025 regarding Anixa Biosciences Inc (ANIX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.